fda ends semaglutide shortage 🚨 The FDA has officially declared an end to the shortage of semaglutide, the active ingredient in the popular medications Ozempic and Wegovy. This announcement signals a significant Ozempic and Wegovy officially moved

Cells 12 , 21 (2022)

January 2026 is aligning with commonly observed early-year interest in oral GLP-1 peptide options, as consumers compare different administration formats during seasonal "new year, new you" wellness behavior

Ozempic is a GLP1 receptor agonist that prompts your pancreas to release more insulin, decreases hepatic glucose production, slows digestion, and affects appetite centers in the brain

Because this is a small-molecule salt rather than a peptide, the usual peptide precautions about mechanical shear and methionine or tryptophan oxidation do not apply

The goal is to minimize the stressors that accelerate degradation or contamination